ReviewHealth science reports2026
BCR-ABL1 Transcript Variants in Chronic Myeloid Leukemia Patients in Africa: A Systematic Review.
Review in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The BCR-ABL1 fusion gene is present in more than 95% of cases of chronic myeloid leukemia (CML), the disease in which it was first described. There are different BCR-ABL1 fusion transcripts depending on the location of the breakpoints during chromosomal translocation. Identifying these transcripts is important for treatment monitoring. The objective was to determine the frequency and distribution of BCR-ABL1 transcripts in African countries. Methods: The articles were sourced from scientific databases such as PubMed, Google Scholar, and the BioMed Central databases. The systematic review was conducted in accordance with the PRISMA guidelines. Data extraction was performed using Excel 2016. Results: Eight original articles, representing seven African countries and involving a total of 1258 patients with CML, were selected based on the established criteria. The mean age of patients at diagnosis was 40.55 years, ranging from 9 to 87 years. The two main transcripts were e14a2 and e13a2. In most African studies, e14a2 was more prevalent than e13a2 (51.35% vs. 38.55%). The Nigerian population showed a relatively high frequency of co-expression of e14a2 and e13a2. The other transcripts identified were e19a2, e1a2, e13a3, and e6a2, accounting for 1.74% of the total number of identified transcripts. Age and sex did not appear to have an effect on transcript types in most countries, with the exception of Sudan and Tunisia. Certain associations were observed between BCR-ABL variants and hematological parameters, particularly white blood cell and platelet counts. Conclusion: There are few studies in Africa on the frequency of BCR-ABL1 gene variants. The main transcripts identified were e14a2 and e13a2. In most cases, the e14a2 variant is more common than the e13a2 variant. Some studies have reported an association with white blood cell and platelet counts in the complete blood count. There is a significant gap in molecular diagnostics in Africa.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.